Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025
Kamada Ltd. (NASDAQ: KMDA), a commercial stage biopharmaceutical company specializing in rare and serious conditions and plasma-derived products, has scheduled its Q1 2025 financial results announcement for May 14, 2025, before U.S. markets open.
The company will host a conference call for the investment community at 8:30am ET on the same day. Participants can join via phone using specific dial-in numbers for U.S., Israeli, and International callers, or watch the webcast live online.
Kamada Ltd. (NASDAQ: KMDA), un'azienda biofarmaceutica in fase commerciale specializzata in condizioni rare e gravi e prodotti derivati dal plasma, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per il 14 maggio 2025, prima dell'apertura dei mercati statunitensi.
La società terrà una conference call per la comunità degli investitori alle 8:30 ET dello stesso giorno. I partecipanti potranno collegarsi telefonicamente utilizzando numeri specifici per chiamate dagli Stati Uniti, Israele e dall'estero, oppure seguire la diretta streaming online.
Kamada Ltd. (NASDAQ: KMDA), una empresa biofarmacéutica en etapa comercial especializada en condiciones raras y graves y productos derivados del plasma, ha programado el anuncio de resultados financieros del primer trimestre de 2025 para el 14 de mayo de 2025, antes de la apertura de los mercados estadounidenses.
La compañía realizará una llamada de conferencia para la comunidad inversora a las 8:30 am ET del mismo día. Los participantes pueden unirse por teléfono utilizando números específicos para llamadas desde EE. UU., Israel e internacionales, o ver la transmisión en vivo en línea.
Kamada Ltd. (NASDAQ: KMDA)는 희귀하고 중대한 질환 및 혈장 유래 제품을 전문으로 하는 상업 단계의 생명공학 제약 회사로, 2025년 5월 14일 미국 시장 개장 전에 2025년 1분기 재무 실적 발표를 예정하고 있습니다.
회사는 같은 날 동부시간 오전 8시 30분에 투자자 대상 컨퍼런스 콜을 개최할 예정입니다. 참가자들은 미국, 이스라엘, 국제 전화를 위한 별도의 전화 접속 번호를 통해 전화로 참여하거나 온라인 실시간 웹캐스트를 시청할 수 있습니다.
Kamada Ltd. (NASDAQ : KMDA), une société biopharmaceutique en phase commerciale spécialisée dans les maladies rares et graves ainsi que les produits dérivés du plasma, a programmé l'annonce des résultats financiers du premier trimestre 2025 pour le 14 mai 2025, avant l'ouverture des marchés américains.
La société organisera une conférence téléphonique destinée à la communauté des investisseurs à 8h30 ET le même jour. Les participants pourront se joindre par téléphone via des numéros d'appel spécifiques pour les États-Unis, Israël et les appels internationaux, ou suivre le webcast en direct en ligne.
Kamada Ltd. (NASDAQ: KMDA), ein biopharmazeutisches Unternehmen in der kommerziellen Phase, das sich auf seltene und schwere Erkrankungen sowie plasma-basierte Produkte spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 14. Mai 2025 vor Öffnung der US-Märkte geplant.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz für die Investoren veranstalten. Teilnehmer können sich telefonisch über spezielle Einwahlnummern für Anrufer aus den USA, Israel und international einwählen oder die Webcast-Liveübertragung online verfolgen.
- None.
- None.
Company to Host Conference Call at 8:30am ET
REHOVOT, Israel, and HOBOKEN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the first quarter that ended March 31, 2025, prior to the open of the U.S. financial markets on Wednesday, May 14, 2025.
Kamada management will host an investment community conference call on Wednesday, May 14, at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.), 1-809-406-247 (from Israel), or 1-201-689-8263 (International) using conference I.D. 1375314. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1715006&tp_key=c9896a4811.
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived therapies field. The Company’s strategy is focused on driving profitable growth through four primary growth pillars: First, organic growth from its commercial activities, including continued investment in the commercialization and life cycle management of its proprietary products, which include six FDA-approved specialty plasma-derived products: KEDRAB®, CYTOGAM®, GLASSIA®, WINRHO SDF®, VARIZIG® and HEPAGAM B®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom products, and the products in the distribution segment portfolio, mainly through the launch of several biosimilar products in Israel. Second: the Company aims to secure significant new business development, in-licensing, collaboration and/or merger and acquisition opportunities, which are anticipated to enhance the Company’s marketed products portfolio and leverage its financial strength and existing commercial infrastructure to drive long-term growth. Third: the Company is expanding its plasma collection operations to support revenue growth through the sale of normal source plasma to other plasma-derived manufacturers, and to support its increasing demand for hyper-immune plasma. The Company currently owns three operating plasma collection centers in the United States, in Beaumont Texas, Houston Texas, and San Antonio, Texas. Lastly, the Company is leveraging its manufacturing, research and development expertise to advance the development and commercialization of additional product candidates, targeting areas of significant unmet medical need, with the lead product candidate Inhaled AAT, for which the Company is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
When will Kamada (KMDA) release its Q1 2025 earnings?
What time is Kamada's Q1 2025 earnings call?
How can investors join Kamada's Q1 2025 earnings call?
What is Kamada's main business focus?
